@FiercePharma: New issues at Ben Venue-J&J's CMO on Doxil-highlight pitfalls of contract manufacturing, WSJ reports. Piece | Follow @FiercePharma
> The Pennsylvania Supreme Court will review Pfizer's ($PFE) challenge to an $8.6 million punitive damages award in a Prempro case. News
> Takeda Pharmaceutical won European approval for its blood pressure drug Edarbi, saying that trials show its superiority to the highest doses of Daiichi Sankyo's Benicar and Novartis' Diovan. Item
> The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK) Singulair, Decision Resources concludes. Release
> Teva Pharmaceutical Industries ($TEVA) won an appeals court's backing for its Fentora patent, shutting out a Watson Pharmaceuticals ($WPI) copy until 2019. Story
> Watson Pharmaceuticals ($WPI) is plotting a 2012 launch for partner Antares Pharma's ($AIS) new treatment for overactive bladder, in a gel form. Article
> Amgen ($AMGN) will buy back about 83.3 million shares at $60 each, or 9.5% of its outstanding stock, as part of a $10 billion repurchase program. Report
> Women using antidepressants for premenstrual syndrome are more likely to get relief if they have multiple physical and psychological symptoms, rather than physical problems alone. More
> Depressive symptoms and impaired physical function tend to persist for long periods after an acute lung injury, a Johns Hopkins study found. Piece
Biotech News
@FierceBiotech: Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Story | Follow @FierceBiotech
@RyanMFierce: Some upbeat Ph2 data in breast cancer from Puma Biotech, which licensed the drug from Pfizer in October. Release | Follow @RyanMFierce
@MaureenFierce: Reading: The loss of the middle (drugs and the people who find them). Story by @Dereklowe | Follow @MaureenFierce
@MarkHFierce: But is the FDA bill an overall improvement? Curious what people think. | Follow @MarkHFierce
@FierceMedDev: Recently profiled them: Bluegrass Vascular starts 1st clinical study of the Surfacer inside-out access catheter system. Release | Follow @FierceMedDev
> Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Item
> J&J locks in blood cancer compound in $975M pact. Story
And Finally... Men using three or more medications have higher rates of erectile dysfunction, according to a study. Report